Blog

Jan 8, 2025, 15:08

Baris Turkbey: Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer

Baris Turkbey, Head of the Magnetic Resonance Imaging section in MIB, shared post on X:

“Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study

– Compared with conventional imaging, addition of PSMA PET leads to M0 downstaging in every third and LVD to HVD upstaging in every fifth metastatic hormone-sensitive prostate cancer patient.

– Future HVD and LVD definitions based on PSMA PET/CT should be adjusted based on patient outcome.”

Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET—An International Multicenter Retrospective Study

Authors: Lena M. Unterrainer et al.

Amar U. Kishan Baris Turkbey cancer Francesco Barbato Honest Ndlovu Johannes Czernin and Jeremie Calais Ken Herrmann Lena M. Unterrainer Matthew B. Rettig Matthias R. Benz Mike Sathekge OncoDaily Oncology Thomas A. Hope Tristan Grogan Wesley Armstrong Wolfgang P. Fendler

The agenda for the 2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents

Elisabetta Zanon Appointed as the New CEO for the European Cancer Organisation

2025 CACA-OncoDaily-SPCC Cancer Summit: Bridging Continents

Breakthroughs in immunotherapy by Steven O’Day and Alexander Eggermont

New Paper Alert: Hepatocellular Carcinoma - Stereotactic Body Radiotherapy vs Sorafenib Alone in the NRG Oncology/RTOG 1112 Phase 3 Randomized Clinical Trial - JAMA Oncology

Special Coverage